IO Biotech
IOBT

$1.14

4.62%

Market Cap: $74.8M

About: IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Employees: 68

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

12% more funds holding

Funds holding: 17 [Q1] → 19 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

4.34% less ownership

Funds ownership: 44.84% [Q1] → 40.49% (-4.34%) [Q2]

39% less capital invested

Capital invested by funds: $51.2M [Q1] → $31.2M (-$19.9M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

252%

upside

Avg. target

$9.33

722%

upside

High target

$12

957%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Matthew Harrison 58% 1-year accuracy 14 / 24 met price target	429%upside $6	Overweight Maintained	16 Sept 2024
HC Wainwright & Co. Emily Bodnar 34% 1-year accuracy 37 / 110 met price target	957%upside $12	Buy Reiterated	16 Sept 2024
Piper Sandler Christopher Raymond 29% 1-year accuracy 8 / 28 met price target	781%upside $10	Overweight Maintained	3 Sept 2024
Morgan Stanley Matthew Harrison 58% 1-year accuracy 14 / 24 met price target	252%upside $4	Overweight Maintained	3 Sept 2024
HC Wainwright & Co. Emily Bodnar 34% 1-year accuracy 37 / 110 met price target	957%upside $12	Buy Reiterated	3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about IOBT published over the past 30 days

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed --

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences: Event: Morgan Stanley 22nd Annual Global Healthcare ConferenceLocation: New York, New YorkFireside Chat Date & Time: Wednesday, September 4, 2024 at 5:35 pm ETPresenter: Mai-Britt Zocca, PhD, CEOWebcast Link: Here Event: H.C. Wainwright 26th Annual Global Investment ConferenceLocation: New York, New YorkPresentation Time: Monday, September 9, 2024 at 10:30 am ETPresenter: Amy Sullivan, CFO Webcast Link: Here A webcast replay of the presentations will be available on IO Biotech's website at www.iobiotech.com for 90 days following the presentation.

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma ; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025 Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN); data from SCCHN cohort has been accepted for poster presentation at the European Society for Medical Oncology (ESMO 2024) congress; abstract with data from NSCLC cohort has been submitted for poster presentation at an upcoming fall medical meeting Completed enrollment in first cohort (cohort A) of Phase 2 solid tumor basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors; initiated enrollment in randomized melanoma cohort Ended second quarter with approximately $100.7 million in cash and cash equivalents; the company confirms that cash position is expected to support operations into the fourth quarter of 2025 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the second quarter ended June 30, 2024. “During the first half of this year, we've continued to execute on our mission of developing breakthrough cancer vaccines that could potentially change the treatment paradigm for people living with melanoma and other types of cancer,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

24/7 Wall Street

3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts

Penny stocks are a fascinating category of investment opportunities.

3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-022/KN-D38 study will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024.

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regarding stock picks through the calculations of those deemed more experienced in understanding financial fundamentals.

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

IO Biotech to Present at Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company's CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York, NY.

IO Biotech to Present at Jefferies Global Healthcare Conference

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024.

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progress poster from the actively recruiting IOB-032/PN-E40 Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) given in the perioperative setting in patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) will be presented.

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

See News Rankings